Actor
Tolerys SA
An early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favourable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG’s manufacturing process and is preparing a first-in-man clinical trial.
Specialties
Primary Therapeutic Areas
1.08 Other Diagnostic & Therapeutic
1.11 Vaccine
Business model
1. Entreprise
1.1 Start-Up
Organization Type
Private Company
Visit website
Domains
Immunology & Allergy, Infectious Diseases
Main sector
Biotech
Contact
Avenue de la Roseraie 64
1205 Geneva / GE
+41 22 372 38 01